Barclays Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price

Incyte (NASDAQ:INCY) had its price objective increased by stock analysts at Barclays from $139.00 to $143.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective would suggest a potential upside of 17.33% from the stock’s previous close.

INCY has been the subject of a number of other reports. Benchmark restated a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. Oppenheimer set a $152.00 price target on Incyte in a research note on Tuesday. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research report on Friday, September 11th. Truist Financial raised their target price on shares of Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, October 14th. Finally, Citigroup restated a “buy” rating on shares of Incyte in a research report on Monday, August 3rd. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Incyte has a consensus rating of “Hold” and an average price target of $132.81.

Incyte Price Performance

NASDAQ:INCY traded up $5.07 during trading hours on Friday, hitting $121.87. The stock had a trading volume of 552,929 shares, compared to its average volume of 1,727,064. The company has a 50 day simple moving average of $120.62 and a two-hundred day simple moving average of $108.07. The firm has a market capitalization of $24.70 billion, a price-to-earnings ratio of 15.48, a P/E/G ratio of 4.83 and a beta of 0.74. Incyte has a one year low of $89.25 and a one year high of $132.60.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter in the prior year, the firm posted $2.26 earnings per share. The business’s quarterly revenue was up 14.0% on a year-over-year basis. Equities research analysts anticipate that Incyte will post 1.97 earnings per share for the current year.

Insider Transactions at Incyte

In other Incyte news, insider Pablo Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Institutional Trading of Incyte

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Incyte during the 2nd quarter valued at $2,044,189,000. Wellington Management Group LLP raised its stake in Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after buying an additional 309,385 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Incyte by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after buying an additional 187,354 shares during the period. Legal & General Group Plc purchased a new position in shares of Incyte in the 2nd quarter worth $182,054,000. Finally, Pacer Advisors Inc. grew its holdings in shares of Incyte by 2.2% in the first quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock worth $163,869,000 after acquiring an additional 37,790 shares during the period. 96.97% of the stock is owned by institutional investors.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly revenue and guidance beat expectations. Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion consensus estimate. Its adjusted loss of $3.60 per share was narrower than expected, and full-year 2026 net-sales guidance increased to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion. Incyte Q3 results and raised guidance
• Positive Sentiment: Key products continued to show healthy demand. Opzelura sales rose 36% to $255 million, prompting higher 2026 guidance of $1.10 billion-$1.12 billion. Hematology and oncology portfolio sales increased 38% to $235 million, while Jakafi and Jakafi XR sales rose 4% to $827 million. Incyte product sales and guidance
• Positive Sentiment: Analyst sentiment provided additional support. Several analysts raised their price targets, and Guggenheim maintained a Buy rating. One forecast cited by Benzinga implies more than 23% potential upside from current levels. Analyst forecasts for Incyte
• Neutral Sentiment: Pipeline activity remains constructive but early stage. Adagene dosed the first patient in a Phase 1 study combining its therapy with Incyte’s INCA33890 in colorectal cancer. The program could expand Incyte’s oncology pipeline, although clinical benefits remain unproven. Adagene and Incyte Phase 1 study
• Negative Sentiment: The headline loss may weigh on shares. Incyte posted a GAAP net loss of approximately $785 million, or $3.86 per share, largely because of a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. Commentary also characterized the valuation gap as largely closed after recent gains, leading one analyst to upgrade the stock only to Hold. Incyte valuation and analyst outlook

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.